ArticleDrug design, development and therapy2019
Diammonium Glycyrrhizinate Mitigates Liver Injury Via Inhibiting Proliferation Of NKT Cells And Promoting Proliferation Of Tregs.
Article in Drug design, development and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Efficacy and safety of glycyrrhizic acid preparation treating comorbid liver injury in COVID-19: A systematic review.Frontiers in pharmacology · 2022Pooled it
- Chinese herbal medicine: Fighting SARS-CoV-2 infection on all fronts.Journal of ethnopharmacology · 2021Pooled it
- Add-on effect of Chinese herbal medicine in the treatment of mild to moderate COVID-19: A systematic review and meta-analysis.PloS one · 2021Pooled it
- Network Pharmacology Analysis of Glycyrrhetinic Acid in Metabolic Dysfunction-Associated Steatotic Liver Disease.Metabolites · 2026Article
- Senkyunolide A interrupts TRAF6-HDAC3 interaction to epigenetically suppress c-MYC and attenuate cholestatic liver injury.Journal of advanced research · 2026Article
- Cellular Metabolomics Reveals Differences in the Scope of Liver Protection Between Ammonium-Based Glycyrrhizinate and Magnesium Isoglycyrrhizinate.Metabolites · 2025Article
- [Research progress on the role of invariant natural killer T cells in immune-mediated liver injury].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Review
- Natural Killer T (NKT) Cells in Autoimmune Hepatitis: Current Evidence from Basic and Clinical Research.Cells · 2023Review
- Saikosaponin-b2 Inhibits Primary Liver Cancer by Regulating the STK4/IRAK1/NF-κB Pathway.Biomedicines · 2023Article
- Lutein Prevents Liver Injury and Intestinal Barrier Dysfunction in Rats Subjected to Chronic Alcohol Intake.Nutrients · 2023Article
- Natural Products as a Potential Source of Promising Therapeutics for COVID-19 and Viral Diseases.Evidence-based complementary and alternative medicine : eCAM · 2023Review
- The role of natural killer T cells in liver transplantation.Frontiers in cell and developmental biology · 2023Review
- [Effects and mechanism of diammonium glycyrrhizinate on liver injury in severely scalded rats].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2022Article
- Targeting Glutamine Metabolism Ameliorates Autoimmune HepatitisFrontiers in immunology · 2022Article
- Prognostic value of antitumor drug targets prediction using integrated bioinformatic analysis for immunogenic cell death-related lncRNA model based on stomach adenocarcinoma characteristics and tumor immune microenvironment.Frontiers in pharmacology · 2022Article
- New insights into iNKT cells and their roles in liver diseases.Frontiers in immunology · 2022Review
- Transcriptome and Lipid Metabolomics-Based Discovery: Glycyrrhizic Acid AlleviatesFrontiers in pharmacology · 2021Article
- The Immunological Mechanisms and Immune-Based Biomarkers of Drug-Induced Liver Injury.Frontiers in pharmacology · 2021Review
- Effect of fucoidan on ethanol-induced liver injury and steatosis in mice and the underlying mechanism.Food & nutrition research · 2021Article
- Immune Cell Landscape in Gastric Cancer.BioMed research international · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDiammonium glycyrrhizinate (DG) is a replacement for glycyrrhizic acid, which is used as a hepatic protector in clinical practice for most liver diseases. The potential role of immune response during autoimmune hepatitis-induced by concanavalin A (Con A)-remains to be elucidated.
methodsC57BL/6J mice were treated with two different doses of DG (75 and 200 mg/kg) 2 hrs before administering Con A. The mice were sacrificed after administering Con A for 0, 6, and 24 hrs. Liver damage grade and serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin levels were evaluated. The expression level of cleaved-caspase 3 in liver was detected by Western blotting. Inflammatory cytokines such as tumor necrosis factor α (TNF-α), interleukin-6 (IL-6), and interferon γ (IFN-γ) in liver were detected by RT-PCR. Thymus, peripheral blood, spleen, and liver tissues were collected to analyze the percentages of NKT cells, subsets of CD4
resultsOur results revealed that DG pre-treatment significantly decreased the serum ALT and AST levels and improved the histological damage in Con A-induced autoimmune liver injury. Pre-treatment with DG down-regulated the inflammatory cytokines upon challenge with Con A. The DG pre-treatment inhibited the apoptosis of T lymphocytes in the thymus. Further, it effectively suppressed the proliferation of CD4
conclusionWe believe that the potential protective effect of DG against Con A-induced hepatitis may be partially attributed to its inhibitory activities on inflammatory cytokines in the livers, lymphocyte apoptosis in the thymus, NKT cells proliferation, and activation of CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.